Crott, Ralph - In: PharmacoEconomics 22 (2004) 9, pp. 569-580
Although interferon alpha (IFN) has been approved since 1995 in the US as adjuvant therapy for high-risk melanoma patients, its cost effectiveness and economic value have only been recently addressed. There are very few papers that address the overall cost and cost components of treating...